Literature DB >> 17492899

Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?

Rudy J Castellani1, Xiongwei Zhu, Hyoung-gon Lee, Paula I Moreira, George Perry, Mark A Smith.   

Abstract

Although amyloid-beta-containing senile plaques and phospho-tau containing neurofibrillary tangles are hallmark lesions of Alzheimer disease (AD), neither is specific for AD, nor even a marker of AD. Rather, they are empirical lesions that require close correlation with age and clinical signs for optimal interpretation. In essence, these lesions represent the effect rather than the cause of disease. In this review, we discuss diagnostic criteria for AD, the relationship between pathology, pathogenesis and multiple treatment approaches that have so far been disappointing, including those that presume to address pathological lesions. An acceptance that lesion-based therapies do not address etiology or rate-limiting pathogenic factors is probably necessary for the best chance of significant advances that have thus far been elusive.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492899     DOI: 10.1586/14737175.7.5.473

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  12 in total

1.  Deferiprone reduces amyloid-β and tau phosphorylation levels but not reactive oxygen species generation in hippocampus of rabbits fed a cholesterol-enriched diet.

Authors:  Jaya R P Prasanthi; Matthew Schrag; Bhanu Dasari; Gurdeep Marwarha; April Dickson; Wolff M Kirsch; Othman Ghribi
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Pathology's new role: defining disease process and protective responses.

Authors:  George Perry; Rudy J Castellani; Paula I Moreira; Hyoung-Gon Lee; Xiongwei Zhu; Mark A Smith
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

Review 3.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

Review 4.  Phosphorylated tau: toxic, protective, or none of the above.

Authors:  Rudy J Castellani; Akihiko Nunomura; Hyoung-gon Lee; George Perry; Mark A Smith
Journal:  J Alzheimers Dis       Date:  2008-08       Impact factor: 4.472

Review 5.  Alzheimer disease pathology as a host response.

Authors:  Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  J Neuropathol Exp Neurol       Date:  2008-06       Impact factor: 3.685

6.  Amyloid Beta and tau proteins as therapeutic targets for Alzheimer's disease treatment: rethinking the current strategy.

Authors:  Siddhartha Mondragón-Rodríguez; George Perry; Xiongwei Zhu; Jannic Boehm
Journal:  Int J Alzheimers Dis       Date:  2012-03-08

7.  Still debating a cause and diagnostic criteria for Alzheimer's disease.

Authors:  Bogdan O Popescu
Journal:  J Cell Mol Med       Date:  2007-11-20       Impact factor: 5.310

8.  BAFF controls neural cell survival through BAFF receptor.

Authors:  Satoru Tada; Teruhito Yasui; Yuji Nakatsuji; Tatsusada Okuno; Toru Koda; Hideki Mochizuki; Saburo Sakoda; Hitoshi Kikutani
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

9.  Context-dependent perturbation of neural systems in transgenic mice expressing a cytosolic prion protein.

Authors:  Henryk Faas; Walker S Jackson; Andrew W Borkowski; Xinhe Wang; Jiyan Ma; Susan Lindquist; Alan Jasanoff
Journal:  Neuroimage       Date:  2009-10-14       Impact factor: 6.556

10.  A Comparison between Extract Products of Magnolia officinalis on Memory Impairment and Amyloidogenesis in a Transgenic Mouse Model of Alzheimer's Disease.

Authors:  Young-Jung Lee; Dong-Young Choi; Sang Bae Han; Young Hee Kim; Ki Ho Kim; Yeon Hee Seong; Ki-Wan Oh; Jin Tae Hong
Journal:  Biomol Ther (Seoul)       Date:  2012-05       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.